Want to see AU:PTX full AI Analyst Report?
PTX Stock Chart & Stats
AU$0.07
>-AU$0.01(-8.70%)
At close: 4:00 PM EDT
AU$0.07
>-AU$0.01(-8.70%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.13
Previous CloseN/A
Volume3.39M
Average Volume (3M)907.05K
Market Cap
AU$66.34M
Enterprise ValueAU$55.34M
Total Cash (Recent Filing)AU$9.03M
Total Debt (Recent Filing)AU$222.97K
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Feb 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,143,850,000
10 Day Avg. Volume513,466
30 Day Avg. Volume907,048
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)4.41
Price to Sales (P/S)0.00
P/FCF Ratio-8.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Targeted Oncology PipelineA pipeline spanning cell-based immunotherapies and targeted small molecules gives Prescient multiple clinical development avenues across hematological malignancies and solid tumors. If candidates advance, this breadth could support future partnering options and reduce dependence on a single therapeutic approach.
Historically Strong Gross MarginsNear-100% gross margins in periods with revenue indicate that the company’s offerings can have attractive economics once commercial or milestone revenue is generated. This provides potential operating leverage, although substantial operating costs currently prevent those gross profits from producing overall profitability.
Low Balance-sheet LeverageLow debt reduces near-term balance-sheet pressure and avoids a significant interest burden while the company funds clinical development. This gives management more flexibility than a highly leveraged biotechnology peer, although the benefit is moderated by declining equity and assets from ongoing cash burn.
Bears Say
Persistent Operating LossesSustained operating and net losses show that Prescient has not yet established a profitable operating model. Continued losses can consume capital needed for clinical programs and increase dependence on future financing, making progress toward sustainable earnings dependent on successful development and revenue generation.
Persistent Cash BurnRecurring negative operating and free cash flow means the business is not self-funding its activities. Ongoing burn can shorten financial runway and require additional external capital, potentially limiting development pace or diluting existing holders if funding is raised through equity.
Revenue And Capital-base DeteriorationThe latest period’s zero revenue removes current operating support for the cost base and weakens visibility into near-term funding capacity. Simultaneous declines in equity and assets indicate that losses are consuming the capital base, increasing execution pressure around clinical milestones and future financing.
Prescient Therapeutics Limited News
PTX FAQ
What was Prescient Therapeutics Limited’s price range in the past 12 months?
Prescient Therapeutics Limited lowest share price was AU$0.04 and its highest was AU$0.13 in the past 12 months.
What is Prescient Therapeutics Limited’s market cap?
Prescient Therapeutics Limited’s market cap is AU$66.34M.
When is Prescient Therapeutics Limited’s upcoming earnings report date?
Prescient Therapeutics Limited’s upcoming earnings report date is Feb 19, 2027 which is in 119 days.
How were Prescient Therapeutics Limited’s earnings last quarter?
Prescient Therapeutics Limited released its earnings results on Aug 20, 2026. The company reported -AU$0.003 earnings per share for the quarter.
Is Prescient Therapeutics Limited overvalued?
According to Wall Street analysts Prescient Therapeutics Limited’s price is currently Overvalued.
Does Prescient Therapeutics Limited pay dividends?
Prescient Therapeutics Limited does not currently pay dividends.
What is Prescient Therapeutics Limited’s EPS estimate?
Prescient Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prescient Therapeutics Limited have?
Prescient Therapeutics Limited has 1,143,850,000 shares outstanding.
What happened to Prescient Therapeutics Limited’s price movement after its last earnings report?
Prescient Therapeutics Limited reported an EPS of -AU$0.003 in its last earnings report. Following the earnings report the stock price went down -2.532%.
Which hedge fund is a major shareholder of Prescient Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:PTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prescient Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:PTX Sentiment 92%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth AU$28.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
32.55%
12-Months-Change
Fundamentals
Return on Equity
-44.93%
Trailing 12-Months
Asset Growth
11.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Prescient Therapeutics Limited
Prescient Therapeutics Limited (PTX.AX) is an Australian clinical-stage oncology firm dedicated to creating novel therapeutic agents for various cancer types. The company's primary experimental compound, PTX-200, is currently undergoing several clinical trials: Phase 2a for HER2-negative breast cancer, Phase 1B/2 for acute myeloid leukemia that has relapsed or is resistant to treatment, and Phase 1b for ovarian cancer that is recurrent, persistent, or resistant to platinum-based therapies. Additionally, PTX-100, a RhoA inhibitor, is being developed to target both blood cancers and solid tumors, specifically those characterized by Ras and RhoA genetic mutations. Prescient Therapeutics has also forged a strategic alliance with The University of Texas MD Anderson Cancer Center to advance the development of a blood cancer binder for their OmniCAR platform. Founded in Melbourne, Australia, in 1986, the company operated as Virax Holdings Limited until its rebranding as Prescient Therapeutics Limited in December 2014.
Technical Analysis
Imugene
―
Immutep Ltd
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―